F-star asset-centric spin-out to target HER2
This article was originally published in Scrip
Making the transition from platform- to product-based operation is a quantum operation, at least for Cambridge antibody company, F-star. The company has won €9.4m from its existing investor pool but the money will go into a separate and unencumbered asset-development vehicle, F-star Alpha which will operate virtually in developing a few of the company's bi-specific antibody candidates. And the lead program will take F-star Alpha into the increasing crowded area of Her2-targeted cancer therapies.
You may also be interested in...
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.
Some of you will be familiar with it, many of you may not even have heard of it, but the pharmaceutical industry needs to know about it; we're talking about Canada's pan-Canadian Pharmaceutical Alliance (pCPA). Currently run with no formal office or resources, by people who have taken it on as extra work on top of their usual day job, the pCPA has still managed to become a formidable market access force in Canada since its inception in 2010. Its decisions are make or break for pharmaceutical companies targeting the market, and changes on the horizon mean its importance is set to increase.